These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12070355)

  • 1. Barriers to drug discovery and development for Alzheimer disease.
    Fillit HM; O'Connell AW; Brown WM; Altstiel LD; Anand R; Collins K; Ferris SH; Khachaturian ZS; Kinoshita J; Van Eldik L; Dewey CF
    Alzheimer Dis Assoc Disord; 2002; 16 Suppl 1():S1-8. PubMed ID: 12070355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers to Alzheimer disease drug discovery and development in the biotechnology industry.
    Altstiel LD
    Alzheimer Dis Assoc Disord; 2002; 16 Suppl 1():S29-32. PubMed ID: 12070359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barriers to Alzheimer disease drug discovery and drug development in the pharmaceutical industry.
    Anand R
    Alzheimer Dis Assoc Disord; 2002; 16 Suppl 1():S33-9. PubMed ID: 12070360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The optimum time for drug licensing.
    Kalamas J; Pinkus G
    Nat Rev Drug Discov; 2003 Sep; 2(9):691-2. PubMed ID: 12953694
    [No Abstract]   [Full Text] [Related]  

  • 5. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success.
    Sugino H; Watanabe A; Amada N; Yamamoto M; Ohgi Y; Kostic D; Sanchez R
    Clin Ther; 2015 Aug; 37(8):1632-42. PubMed ID: 26243073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barriers to Alzheimer disease drug discovery and development in academia.
    Van Eldik LJ; Koppal T; Watterson DM
    Alzheimer Dis Assoc Disord; 2002; 16 Suppl 1():S18-28. PubMed ID: 12070358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease drug development: old problems require new priorities.
    Becker RE; Greig NH
    CNS Neurol Disord Drug Targets; 2008 Dec; 7(6):499-511. PubMed ID: 19128207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease.
    Lahiri DK; Farlow MR; Sambamurti K; Greig NH; Giacobini E; Schneider LS
    Curr Drug Targets; 2003 Feb; 4(2):97-112. PubMed ID: 12558063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents.
    Lahiri DK; Rogers JT; Greig NH; Sambamurti K
    Curr Pharm Des; 2004; 10(25):3111-9. PubMed ID: 15544501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ABC of Alzheimer's disease: cognitive changes and their management in Alzheimer's disease and related dementias.
    Corey-Bloom J
    Int Psychogeriatr; 2002; 14 Suppl 1():51-75. PubMed ID: 12636180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strengthening the Case for Epilepsy Drug Development: Bridging Experiences from the Alzheimer's Disease Field-An Opinion.
    Twyman RE
    Neurochem Res; 2017 Jul; 42(7):2099-2115. PubMed ID: 28589521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.
    Standridge JB
    Clin Ther; 2004 May; 26(5):615-30. PubMed ID: 15220008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural products against Alzheimer's disease: Pharmaco-therapeutics and biotechnological interventions.
    Dey A; Bhattacharya R; Mukherjee A; Pandey DK
    Biotechnol Adv; 2017; 35(2):178-216. PubMed ID: 28043897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ganstigmine. Chiesi.
    Johnson A
    Curr Opin Investig Drugs; 2003 Jul; 4(7):868-73. PubMed ID: 14619410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.
    Arnerić SP; Batrla-Utermann R; Beckett L; Bittner T; Blennow K; Carter L; Dean R; Engelborghs S; Genius J; Gordon MF; Hitchcock J; Kaplow J; Luthman J; Meibach R; Raunig D; Romero K; Samtani MN; Savage M; Shaw L; Stephenson D; Umek RM; Vanderstichele H; Willis B; Yule S
    J Alzheimers Dis; 2017; 55(1):19-35. PubMed ID: 27662307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic considerations in Alzheimer's disease.
    Meek PD; McKeithan K; Schumock GT
    Pharmacotherapy; 1998; 18(2 Pt 2):68-73; discussion 79-82. PubMed ID: 9543467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The adoption of pharmaceutical innovation and its impact on the treatment costs for Alzheimer's disease in Taiwan.
    Lo TF; Hsieh CR
    J Ment Health Policy Econ; 2014 Sep; 17(3):107-17. PubMed ID: 25543114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel disease-modifying therapies for Alzheimer's disease.
    Jiang T; Yu JT; Tan L
    J Alzheimers Dis; 2012; 31(3):475-92. PubMed ID: 22669013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Pharmacogenomics and Biomarkers in the Development of New Drugs for Alzheimer Disease in Japan.
    Otsubo Y
    Clin Ther; 2015 Aug; 37(8):1627-31. PubMed ID: 25963998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.